

rattanawong pattara (Orcid ID: 0000-0001-9419-5854)
kewcharoen jakrin (Orcid ID: 0000-0003-0959-5576)
Kanitsoraphan Chanavuth (Orcid ID: 0000-0001-8222-550X)
Vutthikraivit Wasawat (Orcid ID: 0000-0003-1701-9800)
prasitlumkum narut (Orcid ID: 0000-0002-7956-0574)

Type of syncope and outcome in Brugada syndrome: a systematic review and meta-analysis

Pattara Rattanawong, MD^{1,2}, Jakrin Kewcharoen, MD³, Thanaboon Yinadsawaphan, MD⁴,
Olubadewa Fatunde, MD, MPH¹, Chanavuth Kanitsoraphan, MD⁵, Wasawat Vutthikraivit, MD⁶,
Narut Prasitlumkum, MD⁷, Eugene H. Chung, MD, MPH⁸, Win-Kuang Shen, MD¹

¹ Mayo Clinic, Department of Cardiovascular Medicine, Phoenix, AZ

² Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

³ Division of Cardiology, Cardiac Arrhythmia Service, Loma Linda University Health, Loma Linda, California, USA.

⁴ Central Chest Institution, Bangkok, Thailand

⁵ University of Hawaii Internal Medicine Residency Program, Honolulu, HI, USA

⁶ Division of Cardiovascular, Medicine Department of Internal, Medicine University of Iowa IA.

⁷ Department of Cardiology, University of California Riverside, Riverside, California, USA.

⁸ Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.

Words count: 3,465

Running head: Syncope in Brugada syndrome

Keywords: syncope, Brugada syndrome

Financial Support: None

Acknowledgment: None

Conflict of Interest: None to declare

Ethical approval statement: ethical approval is not required for a systematic review study

Address for correspondence:

Pattara Rattanawong, MD

Mayo Clinic, Department of Cardiovascular Medicine, Phoenix, AZ

PHONE: (808)-859-3848

Email: Pattara.rattanawong@gmail.com

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/joa3.12822](https://doi.org/10.1002/joa3.12822)

This article is protected by copyright. All rights reserved.

Abstract

Introduction: Brugada syndrome is an inherited arrhythmic disease associated with major arrhythmic events (MAE). The importance of primary prevention of sudden cardiac death (SCD) in Brugada syndrome is well recognized; however, ventricular arrhythmia risk stratification remains challenging and controversial. We aimed to assess the association of type of syncope with MAE via systematic review and meta-analysis.

Methods: We comprehensively searched the databases of MEDLINE and EMBASE from inception to December 2021. Included studies were cohort (prospective or retrospective) studies that reported the types of syncope (cardiac, unexplained, vasovagal, and undifferentiated) and MAE. Data from each study were combined using the random-effects, generic inverse variance method of DerSimonian and Laird to calculate the odds ratio (OR) and 95% confidence intervals (CI).

Results: Seventeen studies from 2005 to 2019 were included in this meta-analysis involving 4,355 Brugada syndrome patients. Overall, syncope was significantly associated with an increased risk of MAE in Brugada syndrome (OR=3.90, 95% CI: 2.22-6.85, $p<0.001$, $I^2=76.0\%$). By syncope type, cardiac (OR=4.48, 95% CI: 2.87-7.01, $p<0.001$, $I^2=0.0\%$) and unexplained (OR=4.71, 95% CI: 1.34-16.57, $p=0.016$, $I^2=37.3\%$) syncope was significantly associated with increased risk of MAE in Brugada syndrome. Vasovagal (OR=2.90, 95% CI:

0.09-98.45, $p=0.554$, $I^2=70.9\%$) and undifferentiated syncope (OR=2.01, 95% CI: 1.00-4.03, $p=0.050$, $I^2=64.6\%$, respectively) were not.

Conclusion: Our study demonstrated that cardiac and unexplained syncope was associated with MAE risk in Brugada syndrome populations but not in vasovagal syncope and undifferentiated syncope. Unexplained syncope is associated with a similar increased risk of MAE compared to cardiac syncope.

Abbreviations

VT	ventricular tachycardia
VF	ventricular fibrillation
MAE	major arrhythmic events
OR	odds ratio
CI	confidence intervals

Introduction

Brugada syndrome is characterized by a unique ECG pattern of a coved ST-segment elevation in leads V1-V3 and, by definition, excludes ischemia, electrical conduction disturbances/dysrhythmias, and structural heart diseases¹. Given its pathophysiology, this condition results in syncope and cardiac arrest from polymorphic ventricular tachycardia (VT) with degeneration to ventricular fibrillation (VF)². Nevertheless, it remains unclear which subset of patients with the Brugada pattern will develop these major arrhythmic events (MAE)—especially those without prior documented arrhythmic episodes. While previous studies have identified risk factors associated with MAE in this population^{3,4}, optimal risk-stratification to determine which patients would most benefit from primary prevention is not well validated.

Given the association between syncope and increased risk of sudden cardiac death (SCD) in patients with Brugada syndrome, it remains unclear whether different types of syncope portend different risks of MAE and SCD. There is conflicting data from the previous publications⁵. Hence, we performed this systematic review and meta-analysis to define the association between types of syncope (cardiac, unexplained, vasovagal, and undifferentiated) among patients with Brugada syndrome and the risk of MAE.

Method

Search strategy

Two investigators (JK and CK) independently searched for published studies indexed in MEDLINE and EMBASE databases from inception to November 2021 using a search strategy described in online supplementary document 1 that included the terms “Brugada” and “syncope.” Only English language publications were included. A manual search for additional pertinent studies and review articles using references from retrieved articles was also completed.

Inclusion criteria

The eligibility criteria included the following:

- (1) Observational study (prospective or retrospective cohort or case-control) reporting incidents of MAE, including VF, sustained VT, appropriate shocks, sudden cardiac arrest, or sudden cardiac death, in Brugada syndrome patients with syncope
- (2) Relative risk (RR), hazard ratio (HR), odds ratio (OR), incidence ratio, or standardized incidence ratio with 95% confidence intervals or sufficient raw data for the calculation were provided.
- (3) Brugada syndrome participants without syncope were used as controls.

Study eligibility was independently determined by two investigators (NP and CK), and differences were resolved by mutual consensus. In case of overlap or duplication between populations among studies, the study with the largest sample size and clear definition of syncope from each representative population was selected, whereas the rest of the overlap or duplicated

populations were excluded. If the identity of the declared participating institutions was unclear, the corresponding author of each study was contacted. Newcastle-Ottawa quality assessment scale (Table S1) was used to evaluate each study in three domains: recruitment and selection of the participants, similarity, and comparability between the groups, and ascertainment of the outcome of interest among studies ⁶.

Data extraction

Meta-analysis Of Observational Studies in Epidemiology (MOOSE) has been utilized (Table S2). A standardized data collection form was used to obtain the following information from each study: title of study, name of the first author, year of study, year of publication, country of origin, number of participants, demographic data of participants, the method used to identify cases and controls, the method used to diagnose outcomes of interest (MAE), syncope definition, the average duration of follow-up, confounders that were adjusted, adjusted effect estimates with 95% CI, and covariates that were adjusted for the multivariable analysis.

To ensure accuracy, all investigators independently performed this data extraction process. Any data discrepancy was resolved by referring back to the original articles.

Definition of Syncope type

In this study, we were interested in the correlation between each syncope type in Brugada syndrome patients and MAE. We classified the history of syncope used in the meta-analysis into four groups: cardiac syncope, unexplained syncope, vasovagal syncope, and undifferentiated definition syncope. The information that led to the classification of the four types of syncope from each study is provided in Table 1.

Cardiac Syncope

Cardiac syncope is defined as a transient loss of consciousness due to suspected cardiac arrhythmias (either tachyarrhythmias or bradyarrhythmias) or structural cardiac abnormalities obstructing blood flow⁷. The studies classified as cardiac syncope must define ‘cardiac syncope’ or syncope with suspected arrhythmic origin.

Unexplained syncope

Unexplained syncope, also known as syncope of unknown origin, is described when a cause of syncope cannot be determined despite adequate evaluation⁷. The studies classified as unexplained syncope must define ‘unexplained syncope’ or syncope when no cause was found.

Vasovagal or non-cardiac syncope

Vasovagal syncope is a reflex syncope that frequently occurs in the upright position with a prodrome (ex: diaphoresis, nausea, pallor) followed by fatigue⁷. The studies classified as vasovagal syncope must define syncope as non-cardiac, “vasovagal,” “neurally mediated,” or “reflex” syncope in the studies.

Undifferentiated syncope

Studies provided limited or no data on the characteristics to explain the potential causes of syncope (no definition of syncope was provided in the included studies). Patients from these studies were included in the undifferentiated syncope group for analysis.

Statistical analysis

We performed a meta-analysis of the included studies using a random-effects model. Studies were excluded if they did not present an outcome in each intervention group or did not have enough information required for continuous data comparison. We pooled the point

estimates of OR and RR from each study using the generic inverse-variance method of Der Simonian and Laird ⁸. The heterogeneity of effect size estimates across these studies was quantified using the I^2 statistic. The I^2 statistic ranges in value from 0 to 100% ($I^2 < 25\%$, low heterogeneity; $I^2 = 25\% - 50\%$, moderate heterogeneity; and $I^2 > 50\%$, substantial heterogeneity) ⁹. A sensitivity analysis was performed to assess the influence of the individual studies on the overall results by omitting one study at a time. Publication bias was assessed using a funnel plot and Egger's regression test ¹⁰ ($p < 0.05$ was considered significant) if at least 10 studies were included. All data analyses were performed using Stata SE Statistical Software: Release 14.1, College Station, TX: StataCorp LP, StataCorp 2015.

Sensitivity analysis

We used a sequential exclusion strategy, as described by Patsopoulos and colleagues, to examine whether overall estimates were influenced by the substantial heterogeneity observed ¹¹. In accordance with Cochrane, evidence of publication bias was examined through funnel plots if there were more than ten available studies. Funnel plot asymmetry was further confirmed with Egger's test.

Results

Description of included studies

Our search strategy yielded 1968 potentially relevant articles (1381 articles from EMBASE and 846 articles from MEDLINE). After excluding duplicate articles, 1,587 articles underwent title and abstract review. Following the review, 1,474 articles were excluded as they

were not cohort, case-control, randomized controlled trials, were not conducted in BrS patients, or the titles and abstracts were irrelevant. One hundred and twenty-five articles remained for a full-length review. An additional 113 studies were excluded as they did not report data regarding syncope.

Additionally, they did not provide sufficient data to calculate hazard ratio, risk ratio, or OR. Forty-four studies were excluded because of a duplicated population. Therefore, a total of 17 studies were included in this meta-analysis. Figure 1 outlines the search and literature review process.

Seventeen studies from 2006 to 2019 were included, with 4,355 patients. There were six retrospective cohorts, ten prospective cohorts, and one case-control study from 16 countries. 3390 (77.8%) patients were male, 3340 (76.8%) patients were symptomatic (syncope, documented major arrhythmic event, or previous sudden cardiac arrest) at presentation, mean age of 45.1 ± 12.8 years, and follow-up time was 58.1 ± 45.3 months. Summaries of the included studies and the clinical characteristics are shown in Table 2. The clinical characteristics of syncope and the four types of syncope for the meta-analysis are shown in Table 1.

Meta-analysis results

In the overall analysis, a history of syncope was significantly associated with an increased risk of MAE in patients with Brugada syndrome (pooled OR, 3.90; 95% CI, 2.22–6.85; $p < 0.001$, $I^2 = 76.0\%$). Results from each study were mixed, with ten studies^{4,12-20} reporting the significant association between the history of syncope and risk of MAE, while the other eight studies^{12,21-27} did not find the association to be statistically significant. Only two studies

compared outcomes by syncope type^{12,25} (Table 1). Olde Nordkamp et al. reported a significant association with cardiac syncope but not with vasovagal syncope¹². The Forest plot is shown in Figure 2. Sensitivity analysis showed no significant changes in the results when omitted one study at a time (Supplement Figure 1).

The subgroup analysis of syncope type was performed. Types of syncope were categorized by the definition of syncope stated in each study (Table 1) into four categories: cardiac, unexplained, vasovagal, and undifferentiated syncope. Results for subgroup analysis of cardiac syncope, unexplained syncope, vasovagal, and undifferentiated syncope were available in eight^{4,12-16,19,21}, five^{17,22-25}, two^{12,25}, and four^{18,20,26,27} studies, respectively (Table 1).

The history of cardiac syncope (pooled OR, 4.48; 95% CI, 2.87–7.01; $p < 0.001$, $I^2 = 0.0\%$) and unexplained syncope (pooled OR, 4.71; 95% CI, 1.34–16.57; $p = 0.016$, $I^2 = 37.3\%$) were significantly associated with an increased risk of MAE in patients with Brugada syndrome. For vasovagal syncope (pooled OR, 2.90; 95% CI, 0.09–98.45; $p = 0.050$, $I^2 = 70.9\%$) and undifferentiated syncope (pooled OR, 2.01; 95% CI, 1.00–4.03; $p = 0.05$, $I^2 = 64.6\%$), there were positive trends toward the increased risk of MAE in patients, but the results were not statistically significant.

Quality assessment of included studies

The quality of each study was evaluated by two independent authors (TY, WV). The Newcastle-Ottawa scale (0 to 9) was used to assess included studies on three domains: selection, comparability, and outcomes. Higher scores represent higher study quality. The score of each study ranged from 7 to 9, which reflected high quality (Supplement Table 1). Funnel plots of syncope and MAE are shown in Figure 3. Funnel plots were asymmetric. Egger's test showed significant publication bias ($p < 0.001$) (Supplement Figure 2).

Discussion

In our systemic review and meta-analysis, we analyzed the association between types of syncope and MAE. Seventeen studies from 2006 to 2019 comprising 4355 Brugada syndrome patients were included in the meta-analysis. The major finding was the correlation between a history of cardiac and unexplained syncope with an increased risk of MAE in patients with Brugada syndrome. In contrast, a history of vasovagal syncope and undifferentiated syncope were not significantly associated with an increased risk of MAE in patients with Brugada syndrome.

The history of syncope is one of the most critical factors in predicting arrhythmic events, especially cardiac syncope. A meta-analysis by Gehi and colleagues in 2006—including 30 studies between 1990 to 2005 with 1,545 Brugada syndrome patients—demonstrated that patients with a history of syncope had a 3.2-fold increased risk of cardiac events including SCD, syncope, and appropriate implantable cardioverter-defibrillator (ICD) therapy compared to patients without a history of syncope²⁸. However, no study demonstrated the association between syncope by type and MAE in Brugada syndrome (cardiac, vasovagal, and unexplained syncope). Our meta-analysis, including studies between 2006 and 2019, found that cardiac and unexplained syncope are both associated with a similar 4-5-fold increased risk of MAE.

At the time of diagnosis, approximately 30% of patients with Brugada syndrome either present with syncope or have had a prior syncopal episode. Two previous studies correlated clinical features of syncope (in Brugada syndrome patients) with various etiologies, finding a cardiac cause in 40%, a non-cardiac cause, likely vasovagal, in 30%, and an unexplained cause in approximately 30%^{12,29}. These data further highlight the importance of differentiating cardiac

syncope from other non-cardiac causes of syncope because many of the younger patients with Brugada syndrome have non-cardiac syncope. Types of syncope had a substantial difference in the subsequent risk of MAE.

Previous reviews suggested that vasovagal syncope is frequently observed in Brugada syndrome patients confirmed with a tilt-table test³⁰ and that history-taking with comprehensive risk stratification is essential^{5,31}. However, the previous reviews did not include every study, exclude studies with duplicated populations, nor perform pooled analysis by meta-analysis. Our systematic review and meta-analysis performed a more comprehensive search, systematic review, and meta-analysis that included all studies reported in the previous review with an additional thirteen studies^{13-15,17,18,20,22-27,32} and excluded the duplicated population studies or studies without non-syncope as a control group (supplemental document).

Both cardiac syncope and unexplained syncope are part of the new diagnostic score system. The Shanghai Score was recently proposed by an expert consensus³³ and was validated as new diagnostic criteria for Brugada syndrome³⁴. Shanghai score system allots two points for cardiac syncope but only one for unexplained syncope by expert consensus; however, no study was conducted to assess the difference between cardiac and unexplained syncope. Moreover, a 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline recommends ICD implantation in Brugada patients with cardiac syncope, but unexplained syncope was not stated³⁵. Our meta-analysis is the first study showing that MAE is significantly associated with unexplained syncope with a similar increased risk of MAE compared to cardiac syncope (OR=4.71 and OR=4.48, respectively). Our results suggest that ventricular arrhythmias are likely to be the pathophysiology of unexplained syncope in Brugada syndrome.

All studies included in our meta-analysis that defined their syncope as cardiac syncope had the same trends toward increased risk of MAE without heterogeneity between studies ($I^2=0.0$). However, there was moderate heterogeneity between studies among the unexplained syncope group ($I^2=37.3$). Studies with unexplained syncope patients stated either a cause of syncope could not be found, or there was no prodrome to syncope (Table 1). These inclusion criteria likely selected cohorts with a higher probability of cardiac syncope and less vasovagal syncope.

One observational study, including 23 patients who had a history of suspected cardiac syncope and ICD implantation, showed a MAE rate of 5.5% per year during follow-up. A MAE rate of 3.1% was reported in another study of 88 patients with undifferentiated causes of syncope^{29,36}. This lower rate of MAE in the undifferentiated syncope than in the group with cardiac syncope is not surprising as the undifferentiated group likely included patients with non-cardiac syncope. These findings are consistent with the results from our meta-analysis with larger sample size. The MAE rate is lower in the undifferentiated group. The OR did not reach statistical significance. We suspected that the high heterogeneity in undifferentiated syncope could be explained by variable proportions of cardiac or non-cardiac causes of syncope.

The vasovagal syncope group had positive OR trends towards increased risk of MAE but was not statically significant. With only two studies included in the analysis, there was substantial heterogeneity among the studies. A thorough history is critical in syncope evaluation⁷. The rigor of taking history and interpreting the clinical presentation from the history could have varied among the studies and in the medical training of the healthcare provider. Combined with the lack of standardization of clinical testing, some patients with cardiac causes of syncope could have been included in the vasovagal group. A publication bias was observed in

the overall funnel plot (Figure 2) and confirmed with significant Egger's test.

Several studies in our meta-analysis performed programmed electrical stimulation to risk-stratify Brugada syndrome patients. The usefulness of programmed electrical stimulation in a setting of syncope in Brugada syndrome patients remained to be better defined^{4,19,29}. In a meta-analysis investigating the prognostic value of programmed electrical stimulation in patients with Brugada syndrome, the VT/VF inducibility, irrespective of protocol used, might be helpful to predict subsequent MAE in patients presenting with syncope³⁷. However, another small prospective study demonstrated no difference between VT/VF inducibility and syncope types, including cardiac syncope, vasovagal syncope, and unexplained syncope²⁹. The systematic review for the 2017 guideline on the management of ventricular arrhythmias and prevention of sudden cardiac death showed that the inducibility of VT/VF in asymptomatic patients with Brugada syndrome does not predict higher VA or ICD shocks³⁸. The result from the systematic review led to a IIb recommendation for programmed stimulation for risk stratification in asymptomatic Brugada patients³⁵. The usefulness of programmed stimulation in Brugada patients with syncope is unknown. This could have been another confounder for the equivocal result in the undifferentiated syncope group in our systematic review and meta-analysis.

In a large observational study, Probst et al. showed that patients with a history of suspected cardiac syncope had a lower incidence of developing appropriate ICD shocks during follow-up after ICD implantation, with a 1.9% annual cardiac event rate compared to 7.7% in patients with implanted ICD due to aborted sudden cardiac death. This difference in annual rates of appropriate ICD discharge for "primary" vs. "secondary" sudden cardiac death prevention is similar to other familial conditions such as LQTS³⁹ and hypertrophic cardiomyopathy⁴⁰. Syncope, presumed due to a cardiac cause, remains a factor in the risk stratification for sudden cardiac

death. In 2017, the American College of Cardiology/American Heart Association/Heart Rhythm Society stated that ICD implantation is recommended in Brugada syndrome with spontaneous Type-1 Brugada pattern with a history of cardiac arrest, sustained ventricular arrhythmia, or history of syncope suspected due to ventricular arrhythmia³⁵. Findings from our study further highlight the importance of differentiating cardiac from non-cardiac causes of syncope.

Syncope is a symptom that can be caused by cardiac and non-cardiac conditions. Most patients are asymptomatic when seeking medical evaluation after the index event. Concerns that well-appearing patients may be at significant risk of cardiac arrhythmias or sudden death are particularly relevant in younger patients with familial arrhythmic conditions, including Brugada syndrome. The presumptive diagnosis of cardiac, unexplained, or vasovagal syncope is primarily derived from a thorough history and initial evaluation⁷. The subjectivity of self-reported history, the variability of gathering and interpreting the history, and the lack of standardization of diagnostic testing remain challenging in syncope evaluation. The definition of syncope from each included study in our meta-analysis, summarized in Table 1, is based on the information provided by the investigators of each original study. Some cardiac syncope patients were likely included in the unexplained, vasovagal, and undifferentiated groups. The balance of ICD-mediated benefit vs. ICD-related short- and long-term complications is a derivative of the effectiveness of risk predictors for primary sudden cardiac prevention. A continuing effort to develop algorithms differentiating cardiac vs. non-cardiac syncope is imperative in managing Brugada patients with syncope.

Limitations

There are several limitations to our study. First, all studies in our meta-analysis were observational. Second, there were differences between studies in the thoroughness of history taking, the definition of syncope, the extent of syncope investigation, and established criteria in achieving the diagnosis. Because no definition of syncope was provided in several studies (undifferentiated syncope), the cause of syncope in this subgroup may be overlapped. These were confounders. Well-designed and randomized controlled studies would be ideal, although unlikely, due to the overall small patient population and low MAE rates. Third, specific MAE outcomes reported in the studies varied in their definitions and follow-up durations. Random-effect modeling was used to compensate for these variabilities. Fourth, the included studies were conducted primarily on Caucasian populations from selected databases.

Conclusion

Our systemic review and meta-analysis emphasize that cardiac and unexplained syncope is associated with an increased risk of major arrhythmic events in patients with Brugada syndrome. However, vasovagal and undifferentiated syncope were not. Our meta-analysis result is the first study showing that unexplained syncope is significantly associated with an increased risk of MAE, similar to cardiac syncope. The observation from our meta-analysis supports the practice guideline that recommends that ICDs should be considered in Brugada patients presenting with syncope with suspected arrhythmic causes. Our meta-analysis also advocates further investigations on unexplained syncope as a risk of MAE in this unique patient population with Brugada syndrome.

Acknowledgment: None

Financial Support: None

Conflict of Interest: None to declare

Reference

1. Mizusawa Y, Wilde AA. Brugada syndrome. *Circ Arrhythm Electrophysiol.* 2012;5:606-616. doi: 10.1161/CIRCEP.111.964577
2. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. *J Am Coll Cardiol.* 1992;20:1391-1396. doi: 10.1016/0735-1097(92)90253-j
3. Honarbakhsh S, Providencia R, Garcia-Hernandez J, Martin CA, Hunter RJ, Lim WY, Kirkby C, Graham AJ, Sharifzadehgan A, Waldmann V, et al. A Primary Prevention Clinical Risk Score Model for Patients With Brugada Syndrome (BRUGADA-RISK). *JACC Clin Electrophysiol.* 2021;7:210-222. doi: 10.1016/j.jacep.2020.08.032
4. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, Babuty D, Sacher F, Giustetto C, Schulze-Bahr E, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. *Circulation.* 2010;121:635-643. doi: 10.1161/circulationaha.109.887026
5. Mascia G, Della Bona R, Ameri P, Canepa M, Porto I, Brignole M. Brugada syndrome and syncope: A systematic review. *J Cardiovasc Electrophysiol.* 2020;31:3334-3338. doi: 10.1111/jce.14787
6. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* 2010;25:603-605. doi: 10.1007/s10654-010-9491-z
7. Shen WK, Sheldon RS, Benditt DG, Cohen MI, Forman DE, Goldberger ZD, Grubb BP, Hamdan MH, Krahn AD, Link MS, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation.* 2017;136:e60-e122. doi: 10.1161/CIR.0000000000000499
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* 1986;7:177-188.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327:557-560. doi: 10.1136/bmj.327.7414.557
10. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. *J Clin Epidemiol.* 2001;54:1046-1055.
11. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. *Int J Epidemiol.* 2008;37:1148-1157. doi: 10.1093/ije/dyn065
12. Olde Nordkamp LR, Vink AS, Wilde AA, de Lange FJ, de Jong JS, Wieling W, van Dijk N, Tan HL. Syncope in Brugada syndrome: prevalence, clinical significance, and clues from history taking to distinguish arrhythmic from nonarrhythmic causes. *Heart Rhythm.* 2015;12:367-375. doi: 10.1016/j.hrthm.2014.10.014
13. Gray B, Kirby A, Kabunga P, Freedman SB, Yeates L, Kanthan A, Medi C, Keech A, Semsarian C, Sy RW. Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications. *Heart Rhythm.* 2017;14:866-874. doi: 10.1016/j.hrthm.2017.02.026

14. Sieira J, Conte G, Ciconte G, Chierchia GB, Casado-Arroyo R, Baltogiannis G, Di Giovanni G, Saitoh Y, Juliá J, Mugnai G, et al. A score model to predict risk of events in patients with Brugada Syndrome. *Eur Heart J*. 2017;38:1756-1763. doi: 10.1093/eurheartj/ehx119
15. Subramanian M, Prabhu MA, Rai M, Harikrishnan MS, Sekhar S, Pai PG, Natarajan KU. A novel prediction model for risk stratification in patients with a type 1 Brugada ECG pattern. *J Electrocardiol*. 2019;55:65-71. doi: 10.1016/j.jelectrocard.2019.04.006
16. Takagi M, Aonuma K, Sekiguchi Y, Yokoyama Y, Aihara N, Hiraoka M, Japan Idiopathic Ventricular Fibrillation Study I. The prognostic value of early repolarization (J wave) and ST-segment morphology after J wave in Brugada syndrome: multicenter study in Japan. *Heart Rhythm*. 2013;10:533-539. doi: 10.1016/j.hrthm.2012.12.023
17. Deliniere A, Baranchuk A, Gai J, Bessiere F, Maucort-Boulch D, Defaye P, Marijon E, Le Vavasseur O, Dobreanu D, Scridon A, et al. Prediction of ventricular arrhythmias in patients with a spontaneous Brugada type 1 pattern: the key is in the electrocardiogram. *Europace*. 2019;21:1400-1409. doi: 10.1093/europace/euz156
18. Migliore F, Testolina M, Zorzi A, Bertaglia E, Silvano M, Leoni L, Bellin A, Basso C, Thiene G, Allocca G, et al. First-degree atrioventricular block on basal electrocardiogram predicts future arrhythmic events in patients with Brugada syndrome: a long-term follow-up study from the Veneto region of Northeastern Italy. *Europace*. 2019;21:322-331. doi: 10.1093/europace/euy144
19. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG, Sassone B, Giordano U, Pappone C, Mascioli G, Rossetti G, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELEctrical stimUlation preDICTive valuE) registry. *J Am Coll Cardiol*. 2012;59:37-45. doi: 10.1016/j.jacc.2011.08.064
20. García-Iglesias D, de Cos FJ, Romero FJ, Polana S, Rubín JM, Pérez D, Reguero J, de la Hera JM, Avanzas P, Gómez J, et al. Spectral Analysis of the QT Interval Increases the Prediction Accuracy of Clinical Variables in Brugada Syndrome. *J Clin Med*. 2019;8. doi: 10.3390/jcm8101629
21. Letsas KP, Bazoukis G, Efremidis M, Georgopoulos S, Korantzopoulos P, Fragakis N, Asvestas D, Vlachos K, Saplaouras A, Sakellaropoulou A, et al. Clinical characteristics and long-term clinical course of patients with Brugada syndrome without previous cardiac arrest: a multiparametric risk stratification approach. *Europace*. 2019;21:1911-1918. doi: 10.1093/europace/euz288
22. Kharazi A, Emkanjoo Z, Alizadeh A, Nikoo MH, Jorat MV, Sadr-Ameli MA. Mid-term follow-up of patients with Brugada syndrome following a cardioverter defibrillator implantation: a single center experience. *Indian Pacing Electrophysiol J*. 2007;7:33-39.
23. Leong KMW, Ng FS, Jones S, Chow JJ, Qureshi N, Koa-Wing M, Linton NWF, Whinnett ZI, Lefroy DC, Davies DW, et al. Prevalence of spontaneous type I ECG pattern, syncope, and other risk markers in sudden cardiac arrest survivors with Brugada syndrome. *Pacing Clin Electrophysiol*. 2019;42:257-264. doi: 10.1111/pace.13587
24. Makarawate P, Chaosuwannakit N, Vannaprasaht S, Tassaneeyakul W, Sawanyawisuth K. Clinical characteristics and treatment outcomes of patients with Brugada syndrome in northeastern Thailand. *Singapore Med J*. 2014;55:217-220. doi: 10.11622/smedj.2014055
25. Rivard L, Roux A, Nault I, Champagne J, Roux JF, Tadros R, Talajic M, Cadrin-Tourigny J, Shohoudi A, Mondesert B, et al. Predictors of Ventricular Arrhythmias and

- Sudden Death in a Quebec Cohort With Brugada Syndrome. *Can J Cardiol.* 2016;32:1355 e1351-1355 e1357. doi: 10.1016/j.cjca.2016.03.012
26. Son MK, Byeon K, Park SJ, Kim JS, Nam GB, Choi KJ, Kim YH, Park SW, Kim YH, Park HW, et al. Prognosis after implantation of cardioverter-defibrillators in Korean patients with Brugada syndrome. *Yonsei Med J.* 2014;55:37-45. doi: 10.3349/ymj.2014.55.1.37
 27. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, Yamagishi M, Makita N, Sakurada H, Tanaka T, et al. Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Proband With Brugada Syndrome: A Japanese Multicenter Registry. *Circulation.* 2017;135:2255-2270. doi: 10.1161/CIRCULATIONAHA.117.027983
 28. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. *J Cardiovasc Electrophysiol.* 2006;17:577-583. doi: 10.1111/j.1540-8167.2006.00455.x
 29. Sacher F, Arsac F, Wilton SB, Derval N, Denis A, de Gillebon M, Ramoul K, Bordachar P, Ritter P, Hocini M, et al. Syncope in Brugada syndrome patients: prevalence, characteristics, and outcome. *Heart Rhythm.* 2012;9:1272-1279. doi: 10.1016/j.hrthm.2012.04.013
 30. Yokokawa M, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S, Shimizu W. Neurally mediated syncope as a cause of syncope in patients with Brugada electrocardiogram. *J Cardiovasc Electrophysiol.* 2010;21:186-192. doi: 10.1111/j.1540-8167.2009.01599.x
 31. Mascia G, Bona RD, Ameri P, Canepa M, Porto I, Parati G, Crotti L, Brignole M. Brugada syndrome and syncope: a practical approach for diagnosis and treatment. *Europace.* 2021;23:996-1002. doi: 10.1093/europace/euaa370
 32. Letsas KP, Bazoukis G, Efremidis M, Georgopoulos S, Korantzopoulos P, Fragakis N, Asvestas D, Vlachos K, Saplaouras A, Sakellaropoulou A, et al. Clinical characteristics and long-term clinical course of patients with Brugada syndrome without previous cardiac arrest: a multiparametric risk stratification approach. *Europace.* 2019. doi: 10.1093/europace/euz288
 33. Antzelevitch C, Yan GX, Ackerman MJ, Borggrefe M, Corrado D, Guo J, Gussak I, Hasdemir C, Horie M, Huikuri H, et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. *J Arrhythm.* 2016;32:315-339. doi: 10.1016/j.joa.2016.07.002
 34. Kawada S, Morita H, Antzelevitch C, Morimoto Y, Nakagawa K, Watanabe A, Nishii N, Nakamura K, Ito H. Shanghai Score System for Diagnosis of Brugada Syndrome: Validation of the Score System and System and Reclassification of the Patients. *JACC Clin Electrophysiol.* 2018;4:724-730. doi: 10.1016/j.jacep.2018.02.009
 35. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm.* 2018;15:e73-e189. doi: 10.1016/j.hrthm.2017.10.036
 36. Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gérard F, Mabo P, Reuter S, Lamaison D, Takahashi Y, et al. Outcome after implantation of a cardioverter-

- defibrillator in patients with Brugada syndrome: a multicenter study. *Circulation*. 2006;114:2317-2324. doi: 10.1161/circulationaha.106.628537
37. Fauchier L, Isorni MA, Clementy N, Pierre B, Simeon E, Babuty D. Prognostic value of programmed ventricular stimulation in Brugada syndrome according to clinical presentation: an updated meta-analysis of worldwide published data. *Int J Cardiol*. 2013;168:3027-3029. doi: 10.1016/j.ijcard.2013.04.146
38. Kusumoto FM, Bailey KR, Chaouki AS, Deshmukh AJ, Gautam S, Kim RJ, Kramer DB, Lambrakos LK, Nasser NH, Sorajja D. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2018;138:e392-e414. doi: 10.1161/CIR.0000000000000550
39. Schwartz PJ, Spazzolini C, Priori SG, Crotti L, Vicentini A, Landolina M, Gasparini M, Wilde AA, Knops RE, Denjoy I, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. *Circulation*. 2010;122:1272-1282. doi: 10.1161/CIRCULATIONAHA.110.950147
40. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. *N Engl J Med*. 2000;342:365-373. doi: 10.1056/NEJM200002103420601

Figure and table legends

Table 1: Definition of syncope from each included study

Table 2: Summary of the characteristics of individuals, including studies of patients with Brugada syndrome.

Figure 1: Search methodology and selection process

Figure 2: The forest plot demonstrates the association of syncope and MAE in patients with Brugada syndrome.

Figure 3: Funnel plot of syncope and MAE in patients with Brugada syndrome

Supplement document:

Table S1: Newcastle-Ottawa quality assessment scale of included studies in meta-analysis

Table S2: MOOSE checklist for meta-analysis of observational studies

Figure S1: Sensitivity analysis

Figure S2: Egger tests

Study/Year	Study Design	N	Country	Men (%)	Age (Years)	Brugada ECG Type	Symptomatic BrS (%)	Follow-up (Months)	Outcome
Deliniere et. al., 2019	Retrospective cohort	115	France, Romania, Switzerland	91.3	45.1±12.8	I	39.1	N/A	VF or SCD
Garcia-Iglesias et. al., 2019	Prospective cohort	337	Spain	70.33	41±14.4	I, II, III	32.6	55.8±39.35	VT/VF or SCD appropriate ICD
Gray et. al., 2017	Prospective cohort	54	Australia	81.4	44±13	I	33.3	27.6±30	Clinical (syncopal) aborted sudden death and/or sustained VT/VF
Kharazi et. al., 2006	Case-control study	12	India	91.7	46.5±11.8	I	83.3	27.8±11.3	VF or SCD
Kyun Son et. al., 2014	Retrospective cohort	69	South Korea	98.6	46.2±13.5	I, II, III	79.7	59.0±46.0	Appropriate ICD for VT or VF
Leong et. al., 2018	Retrospective cohort	133	United Kingdom	68.4	44.5±14.8	I	53	42.0±26.0	VT/VF or SCD appropriate ICD
Letsas et. al., 2019	Prospective cohort	111	Greece	77.5	45.3±13.3	I, II, III	33.3	55.2±42.0	VT/VF or SCD appropriate ICD
Makarawate et. al., 2014	Prospective cohort	90	Thailand	97.8	46±5.6	I	87.8	N/A	Appropriate ICD
Migliore et. al., 2019	Prospective cohort	272	Italy	82	43±12	I	30	85.0±55.0	VT/VF or SCD appropriate ICD
Olde Nordkamp et. al., 2014	Retrospective cohort	342	Netherlands	59.9	44±14	I, II, III	41.2	57.5±17.3	Aborted cardiac arrest
Priori et. al., 2012	Prospective cohort	308	Italy	80.2	47±12	I	N/A	36.0±8.0	Appropriate ICD SCD, VF
Probst et. al., 2010	Prospective cohort	1029	France, Germany, Italy, Netherlands	72.4	45±5.8	I, II, III	36.4	33.1±11.7	VT/VF or SCD appropriate ICD
Rivard et. al., 2016	Retrospective cohort	105	Canada	79.0	46.2±13.3	I	44.8	59.6 ± 16.4	Appropriate ICD SCD
Sieira et. al., 2017	Prospective cohort	400	Belgium	58.3	41.1±17.8	I, II	32.8	80.7 ± 57.2	Appropriate ICD SCD

Subramanian et. al., 2019	Retrospective cohort	103	India	86.4	44.5±12.7	I	11.7	72.1±29.2	VT/VF or SCD appropriate ICD
Takagi et. al., 2013	Prospective cohort	460	Japan	93.9	52±14	I	421.9	50.0±32.0	SCD, VF
Yamagata et. al., 2017	Prospective cohort	415	Japan	97.1	46±14	I	45.1	98.5±71.6	Appropriate ICD, ACA, SCD

Table 1: Summary characteristics of individual included studies of patients with a Brugada syndrome

(Abbreviations: CI: confidence interval; ECG: electrocardiogram; ICD: implantable cardioverter-defibrillator; MAE: major arrhythmic events; OR: odds ratio; N/A: not applicable; SCA: sudden cardiac death; SCD: sudden cardiac death; VF: ventricular fibrillation; VT: ventricular tachycardia)

Study/Year	Syncope definition	A phrase or sentence describing term of syncope in the study
Kharazi et. al., 2006	Unexplained	Syncope of unknown origin
Deliniere et. al., 2019	Unexplained	A syncope was defined as a sudden loss of consciousness with rapid recovery, when no cause was found.
Leong et. al., 2018	Unexplained	History of unexplained syncope
Makarawate et. al., 2014	Unexplained	History of unexplained syncope
Priori et. al., 2012	Cardiac	Syncope was defined as an abrupt loss of consciousness occurring at rest or a loss of consciousness during sleep with agonal respiration reported by bystanders.
Rivard et. al., 2016	Vasovagal syncope	History of vasovagal syncope
	Unexplained	History of unheralded syncope (syncope without prodrome)
Kyun Son et. al., 2014	Undifferentiated	Syncope was defined as a transient loss of consciousness accompanied by a loss of postural tone.
Garcia-Iglesias et. al., 2019	Undifferentiated	Symptomatic patients were defined according to the presence of any type of syncope
Migliore et. al., 2019	Undifferentiated	Syncope was defined as a non-traumatic transient loss of consciousness characterized by rapid onset, short duration, and spontaneous complete recovery.
Yamagata et. al., 2017	Undifferentiated	No data were collected on syncope as a cardiac event, because it is difficult to differentiate neurally mediated syncope from truly arrhythmic syncope.
Olde Nordkamp et. al., 2014	Vasovagal	Certain or highly likely reflex syncope and orthostatic hypotension without ECG/Holter documentation of arrhythmia.
Gray et. al., 2017	Cardiac	Arrhythmic syncope
Letsas et. al., 2019	Cardiac	The etiology of syncope was considered arrhythmic in the absence of prodromes and/or typical triggering factors for vasovagal syncope, followed by rapid recovery or severe trauma.
Probst et. al., 2010	Cardiac	Syncope (considered to be probably of arrhythmic origin)
Sieira et. al., 2017	Cardiac	Syncope was considered if suspected to have an arrhythmic origin. Specific attention was paid to excluding vasovagal syncope
Subramanian et. al., 2019	Cardiac	Syncope was defined as abrupt loss of consciousness, probably of arrhythmic origin.
Takagi et. al., 2013	Cardiac	A syncope group with at least 1 episode of syncope without documented VF and with exclusion of etiologies of syncope other than those of cardiac origin

Table 2: Summary of the characteristics of individuals, including studies of patients with Brugada syndrome.





Figure 1 Search methodology and selection process



NOTE: Weights are from random effects analysis

.0009

1

1111

Funnel plot with pseudo 95% confidence limits

